Early detection of cancer is key for improved survival rates as treatment options are more likely to be successful. Liquid biopsy-based early screening tools, however, pose both biological and analytical challenges due to low tumor DNA shedding and the low analytical sensitivity of many existing approaches.
Hybrid capture-based enrichment of differentially methylated regions, combined with computational biology and machine learning approaches, allows researchers to overcome these challenges, delivering highly efficient and uniform analysis of the targets of interest, leading to early and accurate identification of cancer signals.
In this webinar you will:
- Learn how DNA circulating in the blood can be used to detect cancer from very small sample amounts
- Hear how the methylation status of circulating tumor DNA can support early cancer detection
- Discover why Universal Diagnostics partnered with Twist Bioscience to develop their NGS liquid biopsy assay, centered around the hybrid capture of DNA fragments of interest